Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation

Nuclear Medicine and Biology

Volumn 31, Issue 1, 2004, Pages 11-19

  Chen, Xiaoyuan ^a   Park, Ryan ^a   Shahinian, Anthony H ^a   Bading, James R ^a   Conti, Peter S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Angiogenesis; Autoradiography; Integrin; PEGylation; Pharmacokinetics; RGD peptide

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID MONOMETHOXYPOLY(ETHYLENE GLYCOL) I 125; IODINE 125; MACROGOL DERIVATIVE; MONOMETHOXYPOLY(ETHYLENE GLYCOL); RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; DRUG TARGETING; FEMALE; GLIOBLASTOMA; ISOTOPE LABELING; KIDNEY TUBULE ABSORPTION; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PLASMA CLEARANCE; SAMPLING; XENOGRAFT;

EID: 1642533551     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2003.07.003     Document Type: Article

References (29)

1. 111In-DTPA-conjugated peptides. Nucl. Med Biol. 28:2001;761-768.
2. 3 for angiogenesis. Science. 264:1994;569-571.
3. Buerkle M.A., Pahernik S.A., Sutter A., Jonczyk A., Messmer K., Dellian M. Inhibition of the alpha-ν inetgrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumors in vivo. Br J Cancer. 86:2002;788-795.
4. Charon Y., Lanièce P., Tricoire T. Radio-imaging for quantitative autoradiography in biology. Nucl Med Biol. 25:1998;699-704.
5. de Jong M., Rolleman E.J., Bernard B.F., Visser T.J., Bakker W.J., Breeman W.A.P., Krenning E.P. Inhibition of renal uptake of indium-111-DTPA- octreotide in vivo. J Nucl Med. 37:1996;1388-1392.
6. Folkman J. Clinical applications of research onangiogenesis. N Engl J Med. 333:1995;1757-1763.
7. Gottschalk K.-E., Kessler H. The structures of integrins and integrin-ligand complexes implications for drug designand signal transduction . Angew Chem Int Ed. 41:2002;3767-3774.
8. 3 antagonists, J Am Chem Soc. 118:1996;7461-7472.
9. 3 integrin antagonists a new class of tracers for tumor targeting . J Nucl Med. 40:1999;1061-1071.
10. Haubner R., Wester H.-J., Burkhart F., Senekowitsch-Schmidtke R., Weber W., Goodman S.L., Kessler H., Schwaiger M. Glycosylated RGD-containing peptides tracer for tumor targeting and angiogenesis imaging with improved biokinetics . J Nucl Med. 42:2001;326-336.
11. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 61:2001;1781-1785.
12. Heppeler A., Froidevauz S., Mäcke H.R., Jermann E., Béhé M., Powell P., Hennig M. Radiometal-labeled macrocyclci chelator-derivatized somatostatin analog with superb tumor-targeting properties and potential for receptor-mediated internal radiotherapy. Chem Eur J. 5:1999;1974-1981.
13. Ingber D. Extracellular matrix and cell shape potential control points for inhibition of angiogenesis . J Cell Biochem. 47:1991;236-241.
14. 3 integrin binding peptides in a nude mouse model. Cancer Res. 62:2002;6146-6151.
15. Kobayashi H., Le N., Kim I.-S., Kim M.-K., Pie J.-E., Drumm D., Paik D.S., Waldmann T.A., Paik C.H., Carrasquillo J.A. The pharmacokinetic characteristics of glycolated humanized anti-Tac Fabs are determined by their isoelectric points. Cancer Res. 59:1999;422-430.
16. Lawler J., Weinstein R., Hynes R.O. Cell attachment to thrombospondin the role of Arg-Gly-Asp, calcium, and integrin receptors . J Cell Biol. 107:1988;2351-2362.
17. Liekens S., De Clercq E., Neyts J. Angiogenesis regulators and clinical applications . Biochem Pharmacol. 61:2001;253-270.
18. McMurray J.S., Lewis C.A., Obeyesekere N.U. Influence of solid support, solvent and coupling reagent on the head-to-tail cyclization of resin-bound peptides. Peptide Res. 7:1994;195-206.
19. 3 integrin related tumor imaging. Nucl Med Biol. 30:2003;1-9.
20. Robles A.M., Balter H.S., Oliver P., Welling M.M., Pauwels E.K.J. Improved radioiodination of biomolecules using exhaustive Chloramine-T oxidation. Nucl Med Biol. 28:2001;999-1008.
21. Rueegg C., Dormond O., Foletti A. Suppression of tumor angiogenesis through the inhibition of integrin function and signaling in endothelial cells which side to target? Endothelium. 9:2002;151-160.
22. 3-octreotide by conjugation with carbohydrates. Bioconjugate Chem. 13:2002;1021-1030.
23. Sivolapenko G.B., Skarlos D., Pectasides D., Stathopoulou E., Milonakis A., Sirmalis G., Stuttle A., Courtenay-Luck N.S., Konstantinides K., Epenetos A.A. Imaging of metastatic melanoma utilising a technetium-99m labeled RGD-containing synthetic peptide. Eur J Nucl Med. 25:1998;1383-1389.
24. 3 integrin for tumor targeting. Bioconjugate Chem. 13:2002;561-570.
25. Szekanecz Z., Halloran M.M., Haskell C.J., Shah M.R., Polverini P.J., Koch A.E. Mediators of angiogenesis the role of cellular adhesion molecules . Trends Glycosci Glycotechnol. 11:1999;73-93.
26. van Hagen P.M., Breeman W.A.P., Bernard H.F., Schaar M., Mooij C.M., Srinivasan A., Schmidt M.A., Krenning E.P., De Jong M. Evaluation of a radiolabeled cyclic DTPA-RGD analogue for tumor imaging and radionuclide therapy. Int J Cancer. 90:2000;186-198.
27. Veronese F.M. Peptide and protein PEGylation a review of problems and solutions . Biomaterials. 22:2001;405-417.
28. 3 in complex with an Arg-Gly-Asp ligand. Science. 296:2002;151-155.
29. 3. Science. 294:2001;339-345.